BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 33356028)

  • 1. A comparison of mycophenolate mofetil and calcineurin inhibitor as maintenance immunosuppression for kidney transplant recipients: A meta-analysis of randomized controlled trials.
    Deng J; Lu Y; He L; Ou J; Xie H
    Turk J Med Sci; 2021 Jun; 51(3):1080-1091. PubMed ID: 33356028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Belatacept for kidney transplant recipients.
    Masson P; Henderson L; Chapman JR; Craig JC; Webster AC
    Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD010699. PubMed ID: 25416857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients.
    Wagner M; Earley AK; Webster AC; Schmid CH; Balk EM; Uhlig K
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD007746. PubMed ID: 26633102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcineurin inhibitor sparing with mycophenolate in kidney transplantation: a systematic review and meta-analysis.
    Moore J; Middleton L; Cockwell P; Adu D; Ball S; Little MA; Ready A; Wheatley K; Borrows R
    Transplantation; 2009 Feb; 87(4):591-605. PubMed ID: 19307799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
    Tönshoff B; Höcker B
    Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs.
    Flechner SM; Goldfarb D; Solez K; Modlin CS; Mastroianni B; Savas K; Babineau D; Kurian S; Salomon D; Novick AC; Cook DJ
    Transplantation; 2007 Apr; 83(7):883-92. PubMed ID: 17460558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcineurin inhibitor-free mycophenolate mofetil/sirolimus maintenance in liver transplantation: the randomized spare-the-nephron trial.
    Teperman L; Moonka D; Sebastian A; Sher L; Marotta P; Marsh C; Koneru B; Goss J; Preston D; Roberts JP;
    Liver Transpl; 2013 Jul; 19(7):675-89. PubMed ID: 23775875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcineurin inhibitor avoidance and withdrawal for kidney transplantation: a systematic review and meta-analysis of randomized controlled trials.
    Yan HL; Zong HT; Cui YS; Li N; Zhang Y
    Transplant Proc; 2014 Jun; 46(5):1302-13. PubMed ID: 24935293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcineurin-inhibitor free immunosuppression with mycophenolate mofetil and corticosteroids in paediatric renal transplantation improves renal allograft function without increasing acute rejection.
    Krischock L; Gullett A; Bockenhauer D; Rees L; Trompeter RS; Marks SD
    Pediatr Transplant; 2009 Jun; 13(4):475-81. PubMed ID: 18992054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
    Höcker B; Tönshoff B
    Paediatr Drugs; 2011 Feb; 13(1):49-69. PubMed ID: 21162600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized trial comparing late concentration-controlled calcineurin inhibitor or mycophenolate mofetil withdrawal.
    Mourer JS; Hartigh Jd; van Zwet EW; Mallat MJ; Dubbeld J; de Fijter JW
    Transplantation; 2012 May; 93(9):887-94. PubMed ID: 22538450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conversion from calcineurin inhibitor to either mycophenolate mofetil or sirolimus improves renal function in liver transplant recipients with chronic kidney disease: results of a prospective randomized trial.
    Herlenius G; Felldin M; Nordén G; Olausson M; Bäckman L; Gustafsson B; Friman S
    Transplant Proc; 2010 Dec; 42(10):4441-8. PubMed ID: 21168715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcineurin inhibitor sparing with mycophenolate mofetil in liver transplantion: a systematic review of randomized controlled trials.
    Goralczyk AD; Bari N; Abu-Ajaj W; Lorf T; Ramadori G; Friede T; Obed A
    Am J Transplant; 2012 Oct; 12(10):2601-7. PubMed ID: 22813081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure.
    Groetzner J; Kaczmarek I; Schulz U; Stegemann E; Kaiser K; Wittwer T; Schirmer J; Voss M; Strauch J; Wahlers T; Sohn HY; Wagner F; Tenderich G; Stempfle HU; Mueller-Ehmsen J; Schmid C; Vogeser M; Koch KC; Reichenspurner H; Daebritz S; Meiser B; Reichart B;
    Transplantation; 2009 Mar; 87(5):726-33. PubMed ID: 19295318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mycophenolate mofetil and calcineurin-inhibitor reduction: recent progress.
    Grinyó JM; Cruzado JM
    Am J Transplant; 2009 Nov; 9(11):2447-52. PubMed ID: 19775321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale and design of the OPTIMIZE trial: OPen label multicenter randomized trial comparing standard IMmunosuppression with tacrolimus and mycophenolate mofetil with a low exposure tacrolimus regimen In combination with everolimus in de novo renal transplantation in Elderly patients.
    de Boer SE; Sanders JSF; Bemelman FJ; Betjes MGH; Burgerhof JGM; Hilbrands L; Kuypers D; van Munster BC; Nurmohamed SA; de Vries APJ; van Zuilen AD; Hesselink DA; Berger SP
    BMC Nephrol; 2021 Jun; 22(1):208. PubMed ID: 34078323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
    Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
    Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cordyceps sinensis (a traditional Chinese medicine) for kidney transplant recipients.
    Hong T; Zhang M; Fan J
    Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD009698. PubMed ID: 26457607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients.
    Webster AC; Lee VW; Chapman JR; Craig JC
    Cochrane Database Syst Rev; 2006 Apr; (2):CD004290. PubMed ID: 16625599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.